Elevance Health (NYSE:ELV) Issues FY 2026 Earnings Guidance

Elevance Health (NYSE:ELV) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 26.750- for the period, compared to the consensus EPS estimate of 26.910. The company issued revenue guidance of -.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. UBS Group lifted their price objective on Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a report on Friday, May 22nd. Robert W. Baird lifted their price objective on Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a report on Thursday, April 23rd. Morgan Stanley lifted their price objective on Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a report on Thursday, June 4th. Truist Financial lifted their price objective on Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Finally, Weiss Ratings upgraded Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, May 18th. Fourteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $416.11.

Elevance Health Trading Down 1.2%

Elevance Health stock opened at $399.64 on Friday. The business has a 50-day simple moving average of $364.53 and a two-hundred day simple moving average of $344.44. The company has a market cap of $86.79 billion, a P/E ratio of 17.00, a P/E/G ratio of 2.29 and a beta of 0.67. Elevance Health has a 52-week low of $273.71 and a 52-week high of $426.98. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period in the previous year, the company posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Analysts predict that Elevance Health will post 26.93 EPS for the current year.

Elevance Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s payout ratio is currently 29.26%.

Institutional Investors Weigh In On Elevance Health

A number of large investors have recently made changes to their positions in ELV. Larson Financial Group LLC grew its stake in shares of Elevance Health by 9.3% during the 3rd quarter. Larson Financial Group LLC now owns 784 shares of the company’s stock valued at $253,000 after acquiring an additional 67 shares during the period. Transamerica Financial Advisors LLC grew its stake in shares of Elevance Health by 43.9% during the 2nd quarter. Transamerica Financial Advisors LLC now owns 616 shares of the company’s stock valued at $239,000 after acquiring an additional 188 shares during the period. JBF Capital Inc. bought a new position in shares of Elevance Health during the 4th quarter valued at approximately $210,000. Evercore Wealth Management LLC bought a new position in shares of Elevance Health in the fourth quarter worth approximately $203,000. Finally, Sepio Capital LP bought a new position in shares of Elevance Health in the fourth quarter worth approximately $201,000. 89.24% of the stock is currently owned by institutional investors.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.